Artelo Biosciences Announces Closing of $2.0 Million Public Offering

Core Insights - Artelo Biosciences, Inc. has successfully closed a public offering of 441,210 shares of common stock at a price of $4.40 per share, along with pre-funded warrants for an additional 13,335 shares at $4.399 each, generating approximately $2.0 million in gross proceeds before expenses [1][2]. Offering Details - The offering included a 45-day option for underwriters to purchase up to an additional 68,181 shares to cover over-allotments [2]. - The shares and warrants were offered under a "shelf" registration statement filed with the SEC, which became effective on July 14, 2023 [3]. - The final prospectus supplement and accompanying base prospectus were filed with the SEC on October 1, 2025 [4]. Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for various conditions, including cancer, pain, and dermatologic issues [7]. - The company aims to address significant unmet medical needs through a diversified pipeline and is led by an experienced executive team [7].